The US Food and Drug Administration Modernization Act of 1997: Impact on consumers

Clinical Therapeutics

Volumn 20, Issue SUPPL. C, 1998, Pages

  Golodner, Linda F ^a  

^a National Consumers League   (United States)

Author keywords

Consumer; Modernization Act; National Consumers League; Reform

Indexed keywords

CONJUGATED ESTROGEN; DEXFENFLURAMINE; FENFLURAMINE; MIBEFRADIL; NEW DRUG; PHENTERMINE; SIBUTRAMINE; TROGLITAZONE;

ADVERTIZING; CONSUMER; DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG LABELING; DRUG MARKETING; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; PRESCRIPTION; REVIEW; UNITED STATES;

EID: 0032447431     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80004-0     Document Type: Article

References (5)

1. Marwick C. Implementing the FDA Modernization Act. JAMA. 1998;279:815-816.
2. Roche Laboratories. Drug prescribing information. Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co.; 1998:2485.
3. Patient testing and labeling strengthened for Rezulin. FDA Talk Paper. December 1, 1997.
4. Marwick C. Concern expressed about FDA reform legislation. JAMA. 1997;278:459.
5. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA. 1998;279: 1200-1205.